New York, USA, Nov. 28, 2024 (GLOBE NEWSWIRE) — Market Overview:
The global breast cancer liquid biopsy market size was USD 1,209.01 million in 2024, estimated at USD 1,310.56 million in 2025, and is expected to reach around USD 2,731.02 million by 2034, expanding at a CAGR of 8.5% from 2025 to 2034.
What is Breast Cancer Liquid Biopsy?
With the initiation of new approaches, the administration of liquid biopsy has been improved, sanctioning the enhancement of several facets of breast cancer handling involving premature diagnosis and screening, forecast of prognosis, premature observation of deterioration, serial sampling, and productive longitudinal observation of disease advancement and reaction to treatment. Several constituents of tumor cells discharged into the blood circulation can be inspected in liquid biopsy sampling, some of which involve circulating tumor cells, circulating tumor DNA, cell-liberated RNA, tumor-instructed platelets, and exosomes.
Download Free Sample PDF Copy of the Report:
Key Takeaways from the Report
- The market is expected to exhibit a CAGR of 8.5%.
- The market for breast cancer liquid biopsy is expanding due to the inclination towards customized medicines where treatments are customized to distinct patients dependent on the genetic composition of their cancer.
- The breast cancer liquid biopsy market analysis is primarily based on circulating biomarkers, applications, and regions.
- Based on circulating biomarkers, the circulating cell-free DNA (cfDNA) segment dominated the market.
- North America dominated the market with the largest share and is anticipated to continue its dominance during the forecast period.
Breast Cancer Liquid Biopsy Market Dynamics:
Growth Drivers:
Technological Progressions: The breast cancer liquid biopsy market size is expanding due to growing technological progressions such as inventions in molecular biology, next-generation sequencing, and progressive ctDNA discernment technologies. Additionally, the instigation of contemporary progressive assays for tumor discernment has notably pushed the market growth. In November 2023, Illumina Inc. instigated a refurbished category of its disseminated liquid biopsy assay, the TruSight Oncology 500 ctDNA v2.
Growth in Cases of Blood Cancer: The growing cases of blood cancer worldwide, particularly in advanced regions, caused an elevated requirement for noninvasive diagnostic methodologies such as liquid biopsy for premature discernment and disease observation. In 2022, as per the Breast Cancer Research Foundation report, roughly 2.3 million women were detected with cancer, and approximately 0.67 million deaths were registered due to cancer prevalence globally.
Trends and Opportunities
Premature Cancer Detection: Liquid biopsies are important instruments for clinicians and patients sanctioning premature cancer discernment and ongoing observation of tumor aggression involving treatment reaction. This is pushing the acquisition of liquid biopsies for blood cancer which is crediting to market growth. Additionally, the growing aggregate of administrative consent for liquid biopsy examinations, especially by bodies such as the US Food and Drug Administration, is suggesting that the breast cancer liquid biopsy market demand is expanding.
Growth in Usage of Clinical Trials: Liquid biopsies are growingly being utilized in clinical trials for breast cancer drug advancement as they offer a real-time noninvasive procedure for observing drug productivity and illness advancement, which is fueling the market growth.
Inquire more about this report before purchase:
Competitive Analysis:
The aggressive topography of the market is portrayed by an assorted array of critical players involving entrenched biotechnology firms, surfacing startups, and academic bodies all struggling to invent and seize market share. Prominent firms such as Guardant Health, GRAIL, Freenome, and Foundation Medicine are at the vanguard of developing progressive liquid biopsy assays that use circulating tumor DNA and circulating tumor cells for premature cancer inspection and observation. The aggressive topography is also distinguished by notable funding in research and development, with firms struggling to acquire administrative consent for their assays.
Major players operating in the breast cancer liquid biopsy market are:
- Biocept, Inc.
- Epic Sciences, Inc.
- F. Hoffmann – La Roche Ltd.
- Fluxion Biosciences, Inc.
- Myriad Genetics, Inc.
- NeoGenomics Laboratories
- QIAGEN
- Sysmex Corporation
- The Menarini Group
- Thermo Fisher Scientific, Inc.
Regional Insights:
North America: The region’s progressive healthcare framework and elevated acquisition rates of inventive diagnostic techniques have eased the extensive usage of liquid biopsy methods, which has accounted for the largest share of the market in 2024.
Asia Pacific: The growing funding in progressive diagnostic framework enhancing the obtainability of progressive cancer screening inspection is expected to drive the Asia Pacific breast cancer liquid biopsy market with the highest CAGR during the forecast period.
Breast Cancer Liquid Biopsy Market Segmentation:
By Circulating Biomarkers Outlook
- Circulating Tumor Cells (CTCs)
- Circulating Cell-Free DNA (cfDNA)
- Extracellular Vesicles (EVs)
- Other Circulating Biomarkers
By Application Outlook
- Early Detection/Screening
- Diagnosis
- Treatment Selection
- Monitoring
By Regional Outlook
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of the Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
More Trending Latest Reports by Polaris Market Research:
Advanced Wound Care Management Market Share
X-Ray Photoelectron Spectroscopy Market Growth
Audiology Devices Market Analysis
Hypertension Drug Market Forecast
About Polaris Market Research & Consulting, Inc:
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR’s clientele spread across different enterprises. We at Polaris are obliged to serve PMR’s diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR’s customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR’s customers.
Contact:
Likhil G
8 The Green Ste 19824,
Dover, DE 19901,
United States
Phone: +1-929 297-9727
Email: sales@polarismarketresearch.com
Web: https://www.polarismarketresearch.com
Follow Us: LinkedIn | Twitter
